Canaccord Genuity Downgrades Impax Laboratories (IPXL) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Downgrades Impax Laboratories (IPXL) to Market Perform
March 5, 2013 7:22 AM ESTLeerink Swann downgraded Impax Laboratories (NASDAQ: IPXL) from Outperform to Market Perform with a price target of $16.00 (from $23.00) after the FDA's follow-up inspection of IPXL's Hayward facility uncovered additional manufacturing deficiencies.
"Our prior thesis that IPXL would resolve its mfg.... More
Impax Labs (IPXL) Receives New Form 483 for Hayward Facility
March 4, 2013 4:15 PM ESTImpax Laboratories, Inc. (NASDAQ: IPXL) announced that the U.S. Food and Drug Administration (FDA) completed its re-inspection of the Companys Hayward manufacturing facility in connection with the previously disclosed Form 483 issued in March 2012. In addition to the re-inspection, the FDA conducted a Pre-Approval Inspection (PAI) for RYTARYTM, as analytical method validation and a portion of the stability data were generated in Hayward, and a general Good Manufacturing Practices (GMP) inspection. At the conclusion of this... More
Impax Labs (IPXL) trading halted with news pending
March 4, 2013 4:01 PM ESTImpax Labs, Inc. (NASDAQ: IPXL) trading halted with news pending.... More
